Ardelyx, Inc. ARDX
We take great care to ensure that the data presented and summarized in this overview for ARDELYX, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARDX
View all-
Janus Henderson Group PLC London, X021.5MShares$103 Million0.08% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$84.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$65.3 Million0.0% of portfolio
-
State Street Corp Boston, MA12.1MShares$58.3 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C38.95MShares$43 Million0.07% of portfolio
-
Eventide Asset Management, LLC Boston, MA7.41MShares$35.6 Million0.9% of portfolio
-
Geode Capital Management, LLC Boston, MA5.49MShares$26.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.01MShares$19.3 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.13MShares$15 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY3.06MShares$14.7 Million0.59% of portfolio
Latest Institutional Activity in ARDX
Top Purchases
Top Sells
About ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Transactions at ARDX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 19
2024
|
David M Mott Director |
BUY
Open market or private purchase
|
Direct |
213,300
+11.52%
|
$853,200
$4.67 P/Share
|
Dec 10
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.13%
|
$125,000
$5.26 P/Share
|
Dec 10
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.08%
|
$0
$0.99 P/Share
|
Nov 25
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.13%
|
$125,000
$5.38 P/Share
|
Nov 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
2,243
-1.46%
|
$8,972
$4.79 P/Share
|
Nov 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,941
-1.64%
|
$19,764
$4.79 P/Share
|
Nov 20
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,366
-2.33%
|
$29,464
$4.79 P/Share
|
Nov 20
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
31,980
-2.65%
|
$127,920
$4.79 P/Share
|
Nov 20
2024
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,260
-1.77%
|
$21,040
$4.79 P/Share
|
Nov 20
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
4,941
-1.55%
|
$19,764
$4.79 P/Share
|
Nov 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
7,046
-3.66%
|
$28,184
$4.79 P/Share
|
Nov 13
2024
|
David M Mott Director |
BUY
Open market or private purchase
|
Direct |
215,868
+13.15%
|
$863,472
$4.62 P/Share
|
Nov 11
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
2,743
-0.23%
|
$10,972
$4.9 P/Share
|
Nov 06
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
27,171
-15.03%
|
$163,026
$6.1 P/Share
|
Nov 06
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
27,171
+13.07%
|
$54,342
$2.32 P/Share
|
Nov 04
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
27,172
-15.03%
|
$135,860
$5.95 P/Share
|
Nov 04
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
27,172
+13.07%
|
$54,344
$2.32 P/Share
|
Oct 28
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.02%
|
$125,000
$5.91 P/Share
|
Oct 28
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+1.98%
|
$0
$0.99 P/Share
|
Oct 11
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.62%
|
$45,000
$6.01 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.71M shares |
---|---|
Open market or private purchase | 429K shares |
Exercise of conversion of derivative security | 799K shares |
Bona fide gift | 1K shares |
---|---|
Open market or private sale | 1.81M shares |